A copy of the presentation materials can be accessed on the News & Events section under “Presentations” of the Company’s website at www.compasstherapeutics.com once the presentation has concluded.
The abstract and oral presentation outlining the FIH trial is entitled, “AGA2118, a Bispecific Antibody Neutralizing both Sclerostin and DKK1, Increased Bone Formation, Decreased Bone Resorption, and ...